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Abstract
Classical drug therapies against prion diseases have encountered serious difficulties. It has become urgent to develop
radically different therapeutic strategies. Previously, we showed that VSV-G pseudotyped FIV derived vectors carrying
dominant negative mutants of the PrP gene are efficient to inhibit prion replication in chronically prion-infected cells.
Besides, they can transduce neurons and cells of the lymphoreticular system, highlighting their potential use in gene
therapy approaches. Here, we used lentiviral gene transfer to deliver PrPQ167R virions possessing anti-prion properties to
analyse their efficiency in vivo. Since treatment for prion diseases is initiated belatedly in human patients, we focused on the
development of a curative therapeutic protocol targeting the late stage of the disease, either at 35 or 105 days post-
infection (d.p.i.) with prions. We observed a prolongation in the lifespan of the treated mice that prompted us to develop a
system of cannula implantation into the brain of prion-infected mice. Chronic injections of PrPQ167R virions were done at
80 and 95 d.p.i. After only two injections, survival of the treated mice was extended by 30 days (20%), accompanied by
substantial improvement in behaviour. This delay was correlated with: (i) a strong reduction of spongiosis in the ipsilateral
side of the brain by comparison with the contralateral side; and (ii) a remarkable decrease in astrocytic gliosis in the whole
brain. These results suggest that chronic injections of dominant negative lentiviral vectors into the brain, may be a
promising approach for a curative treatment of prion diseases.
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Introduction
Transmissible spongiform encephalopathies (TSEs), or prion
diseases, are fatal neurodegenerative disorders in humans and
animals for which no effective therapy exists. The pathogenesis of
prion diseases is based on the presence of PrP
Sc, a protease-
resistant isoform of the normal cellular prion protein called PrP
C
[1,2]. The progressive accumulation of PrP
Sc in the brains of
affected individuals, which can occur for up to 20 years, is
associated with the neurodegeneration.
During the last decade, the BSE crisis in Europe and the
transmission of the BSE infectious agent to humans have placed
prion diseases on centre stage [3]. The emergence of acquired
forms of human TSEs in younger people, such as variant CJD
(vCJD) and iatrogenic CJD (iCJD) resulting from contaminated
cadaveric growth hormone mostly in France [4] or dura grafts in
Japan [4], have highlighted the urgent need for effective
treatments. Furthermore, two recent studies have reported vCJD
cases likely resulting from the transfusion of prion-contaminated
blood [5,6], raising concerns about the safety of blood products as
well as the possibility of a second epidemic of vCJD.
The identification of compounds possessing anti-prion activity,
such as porphyrin and phtalocyanin derivatives [7] or anti-PrP
antibodies [8], has allowed a substantial improvement in the
survival time of animals. However, these molecules are only
maximally effective when administered at or near the time of prion
inoculation, before the infectious agent can reach the central
nervous system. The efficacy of these compounds at early stages of
the disease suggests that they might best be used for post-exposure
prophylactic or preclinical treatments [9]. Unfortunately, early
treatment is impossible in human patients because the disease can
only be detected after the onset of neurological symptoms, even in
familial cases. Recently, intraventricular infusion of Pentosan
Polysulfate (PPS) into mice at 35 days post-inoculation with prions
gave a delay of 36 days in the mean incubation time, but severe
adverse effects in the animals were observed [10]. Administration
of such a high dose in humans is not appropriate because of the
risk of urinary infections, haemorrhage, seizure, and death
[10,11]. A recent article reporting the continuous intraventricular
administration of approximately 1–110 mg/kg/day of PPS over 18
days in a human patient concluded that the drug cannot be used
for the treatment of human TSE [12]. In addition, quinacrine and
chlorpromazine have been described as efficient inhibitors of PrP
Sc
formation in neuroblastoma cells [13,14]. As these medications
had already been approved for the treatment of malaria and
various psychoses, they were administered as a ‘‘compassionate
treatment’’ to patients suffering from sporadic CJD or vCJD. No
therapeutic effect, however, was observed following quinacrine
treatment in 20 patients [10,15,16].
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and that the time has come to examine radically different
strategies. Since natural resistance to prion diseases exists in
animals and humans [17–20] and has been extensively studied
both in vitro [21,22] and in vivo [23–27], we took advantage of
these dominant negative inhibition properties by pursuing an
innovative therapeutic concept : Can prion diseases be treated
with the prion protein itself?
In a previous article, we reported that VSV-G (vesicular stomatitis
virus G glycoprotein) pseudotyped FIV (Feline Immunodeficiency
Virus) lentiviral vectors carrying dominant negative mutant forms of
the mouse Prnp gene (PrPQ167R or PrPQ218K) were able to inhibit
prion replication in prion-infected cells [28]. In situ injections
performed in healthy mice showed that the lentiviral vectors could
transduce both neurons and cells of the lymphoreticular system,
highlighting their potential use in gene therapy approaches for the
treatment of prion diseases [28]. Since treatment for prion diseases is
generally initiated very late in humans, partly because of the lack of
an early diagnosis test, we focused on the development of a curative
therapeutic protocol targeting the late stage of the disease, either at
35 or 105 days post-infection (d.p.i.) with prions. A prolongation in
the lifespan of treated mice prompted us to develop a system of
cannula implantation into the brain of prion-infected mice. Chronic
injections of PrPQ167R virions were done at 80 and 95 d.p.i. After
only two injections, survival of the treated mice was extended by 30
days (20%), accompanied by substantial improvement in behaviour.
Brain tissue analysis of mice treated with PrPQ167R virions
indicated a remarkable decrease in astrocytic gliosis throughout
the brain, suggesting that the PrPQ167R variant could play a key
role in preventing the activation of inflammatory processes.
Materials and Methods
Reagents and Antibodies
Pefabloc and proteinase K were purchased from Roche.
Ketamine was obtained from Me ´rial (Lyon, France) and xylazine
from Bayer HealthCare (Puteaux, France). Anti-PrP antibodies,
SAF32, SAF60, SAF69, SAF70, and SAF84 were kindly provided
by Dr. Jacques Grassi (CEA, Saclay, France) [28]. Anti-GFAP
antibodies were purchased from AbCys (Paris). For immunohis-
tology, the secondary antibody was provided in the Strept ABC
Complex Kit (AbCys, Paris). Immunoblot secondary antibodies
were from Jackson ImmunoResearch (West Grove, PA). All other
chemicals were from Sigma (Paris).
Animal models
C57Bl/6J mice were purchased from Charles River (Arbresle,
France) and Janvier (Le Genest-St-Isle, France) breeding labora-
tories. The Me7 prion strain was provided by Richard Carp (New
York Institute, NY, USA). Mice were intracerebrally inoculated in
the right parietal portion of the brain with 20 ml of 1% brain
homogenate (w/v) in PBS corresponding to 2610
5 LD50. Groups
of five mice were housed in cages placed in a ventilated protective
cabinet. All experiments were carried out in a biohazard security
level laboratory and according to ethical committee guidelines
(Comite ´r e ´gional d’e ´thique de Montpellier, project agreement nu
CE-LR-0609; animal experiment authorization nu 34.213). Mice
were scored positively for prion disease when three signs of
neurologic dysfunction were present, and when progressive
deterioration of the animal was apparent according to 16
diagnostic criteria, as previously described [29,30]. Once clinical
signs were detected, the animals were sacrificed in extremis. Their
brains were taken and either immediately frozen at 280uCo r
fixed in AntigenFix (Diapath) for immunohistochemistry analysis.
Nomenclature
The Q/R polymorphism at codon 171 in sheep corresponds to
the Q167R mutation in mice. Virions containing the PrPQ167R
gene are termed YPrPQ167R. The control virions containing only
the GFP gene are termed YGFP.
Production of lentiviral vectors carrying the dominant
negative PrPQ167R mutant
The construction of lentiviral vectors containing the mutated
gene coding for PrPQ167R and the production of lentivirus in
293T cells were performed as previously described in Crozet et al.
(2004) [28]. The transfer vector contains the mutated PrP
sequence, followed by an internal ribosome entry sequence
(IRES), and the enhanced green fluorescent (GFP) protein marker
gene (Figure 1A). This IRES sequence allows the determination of
the infectious titer of the virions by measuring the fluorescence of
the GFP proteins after transduction of 293T cells. The infectious
titer of the YPrPQ167R, determined by FACS analysis, was
4.2610
7 transforming unit/ml (T.U./ml). The infectious titer of
the empty virions (YGFP) was 9610
9 T.U./ml. Transduction into
Prnp
2/2 cells (generous gift of T. Onodera) was carried out to
confirm the expression of our lentivirus before performing in vivo
experiments, as described in Crozet et al. (2004) [28].
Surgery for implantation of guide cannula
Seventy days post-inoculation (p.i.) with prions, each mouse
underwent surgery to implant a guide cannula into its brain
(Plastics One, Roanoke,VA). Using a stereotaxic frame (Kopf
Instruments, Tujunga, CA), the guide cannula was fixed in the
hippocampal brain region according to the following coordi-
nates: L: 1.2 mm; R: 21.8 mm; P: 22.0 mm (Paxinos and
Franklin stereotaxic Atlas, 1997). The guide cannula allows the
formation of a stable aperture in the brain through which
treatments can be administered. In the absence of treatment,
the guide cannula contains an obturator which prevents the
aperture from being filled in by surrounding tissue. A
cicatrization delay of about 10 days is necessary before realizing
the first treatment.
Administration of treatments in mice
Single injections of virions or PBS were done in the
hippocampal area of mouse brain (coordinates : L: 1.2 mm; R:
21.8 mm; P: 22.0 mm Paxinos and Franklin stereotaxic Atlas,
1997) using a stereotaxic frame. At 35 or 105 days p.i. with prions,
anesthetized mice received 2610
5 T.U. of virions or PBS, at a rate
of 0.5 ml/min, allowing slow diffusion.
Groups of mice that received two injections of virions received
the treatment through an internal cannula fixed to the guide and
a connector linked to an automatic pump. At 80 and 95 days p.i.
with prions, 2610
5 T.U. of YPrPQ167R or YGFP were
administered in situ in mice brain at a rate of 0.5 ml/min,
allowing slow diffusion. In addition, injections of vector doses
below 1610
8 T.U do not induce any innate increased recruit-
ment of inflammatory cells to the brain, and do not cause glial or
neuronal toxicity [31].After surgery, each mouse was kept in an
individual cage to prevent the removal of the guide cannula by
other animals. Mice awoke around 30–60 min after surgery.
Then, they remained under daily observation for one week for
possible suffering, and twice a week until 140 days p.i. Starting at
140 days after prion infection, mice were observed daily for
possible neuropathological signs. Movies of mice were made at
172 and 189 days p.i. with prions using a digital video camera
recorder.
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Brain tissues were homogenized in 10% (w/v) PBS using
microbead-containing tubes and a Ribolysor apparatus (Biorad,
Marnes-la Coquette, France). Samples were shaken for 45 sec. and
supernatants collected through an insulin syringe (Terumo) to
obtain a homogeneous suspension. Proteinase K digestion of brain
samples was performed as described [27]. Undigested samples
were prepared by mixing an aliquot of 10% brain homogenate
with an equal volume of SDS loading buffer and were then boiled
for 5 min. Thirty microliters of the PK-treated or undigested
samples were loaded onto 12% SDS/PAGE Precast gels (Criterion
system from BioRad). Immunoblots were performed using
standard procedures. The PrP
Sc protein was detected using a
mixture of three monoclonal antibodies (SAF60, SAF69 and
SAF70), called SAFmix, as previously described [32]. The normal
PrP
C protein was detected with SAF32 monoclonal antibodies.
Immunohistochemistry analysis
Brain tissue was first immersed in Antigenfix solution (DiaPath,
France) for 24 h. Then, they are decontaminated for 30 min in a
formic acid solution according to protocol described by Andre ´o-
letti et al.(2004) [33] and stored in 100 mM phosphate buffer at
pH 7.4 with 0.02% azide. Samples were dehydrated in graded
ethanol, cleared in cedar oil, and then embedded in paraffin.
Frontal tissue sections were cut at six to ten micrometers using a
microtome and mounted on superfrost plus slide glasses (Microm
France, Francheville). Sections were dewaxed and stained with
hematoxylin and eosin. Immuno-labelling using anti-glial fibrillary
acidic protein (anti-GFAP) antibodies was performed according to
the instructions provided with the Strept ABC Complex Kit.
Immune reactions were visualized using 3-39-diaminobenzidine
(DAB) chromogen solution (Sigma, France). PrP
Sc immunohisto-
chemistry was performed on dewaxed tissue sections, which were
Figure 1. Schematic representation of the transfer vector used for virions preparation (A). The transfer vector was derived from the
prototypic FIV-14-Petaluma genome (AIDS Research and Reference Reagent Program) [28]. The U3 region of the 59 LTR was replaced with CMV
promotor in order to express the vector in the cells. The gag gene was truncated at position 1243 and a frameshift was introduced at position 926.
The pol, vif, orfA, env and rev genes were replaced by a cassette containing the mutated PrPQ167R gene driven by the phosphoglycerate kinase
promotor (PGK). The PrP gene is followed by an IRES sequence and enhanced GFP gene. As a control vector, we used a transfer vector containing
only the GFP gene without the PrP sequence. Schema of the therapeutic protocol assayed in a mouse model of prion disease (B). C57Bl/6
mice inoculated with Me7 prion strain developed a prion disease detectable after 150 days post-infection (p.i.). The prion agent first replicates in the
peripheral sites, especially the lymphoreticular system, before the neuroinvasion of the central nervous system (CNS). PrP
Sc is detectable in the spleen
at 30 days p.i. and the spongiosis is visible in the brain at about 80 days p.i. [34]. Preclinical treatments (1–30 days) target the prion agent during its
replication in the lymphoreticular system and before the neuroinvasion of the CNS. Curative treatments (30–160 days) target the infectious agent
after the neuroinvasion of the CNS. To evaluate the possible curative effect of YPrPQ167R, several protocols were tested : (i) a unique injection of
YPrPQ167R at 35 or 105 days p.i. (printed in blue); and (ii) two administrations of the YPrPQ167R at 80 and 95 days p.i. (printed in red). Picture of a
C57Bl/6 mouse with a guide cannula implanted into its brain (C). An obturator has been fitted into the guide-cannula to prevent the channel
from being blocked by tissue regeneration.
doi:10.1371/journal.pone.0002773.g001
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water and incubated at 121uC for 1 h. Then, the slides were
submitted to a proteinase K treatment (20 mg/ml) for 20 min at
37uC, rinsed in Tris Buffer Saline (TBS), and incubated overnight
with the primary antibody SAF84 (1/500) at 4uC. After several
rinses, the slides were incubated with the secondary antibody (anti-
mouse IgG 1/100). Immune reactions were visualized using 3-39-
diaminobenzidine (DAB) chromogen solution (Sigma, France).
Tissue sections of each group were treated identically with the
same incubation time for comparative analysis.
Software and statistical analysis
For animal experiments, we used the Kruskal and Wallis test with
a probability of 0.05 defined as a significant difference, followed by
Scheffe ´ test used for comparison of each group of mice versus PBS-
treated animals (Statview 5, Abacus concept,Berkeley, CA). Survival
curves were done using GraphPad Software (San Diego, CA).
Mercator (Explora Nova, La Rochelle, France) was used for the
counting of vacuoles and GFAP-labelled cells in histological
sections. Following a significant one-way ANOVA, we used the
Fisher PLSD test for multiple comparisons, with a probability of
0.05 defined as a significant difference.
Results
PrPQ167R virions increased the survival time of prions-
inoculated mice
C57Bl/6 mice inoculated with the Me7 prion strain are an
effective model of prion diseases that have been well described for
their incubation time, vacuolization profiles, and immunohistology
[34,35].Thesemicedevelopsignificantvacuolization(scored3outof
5) in the hippocampus, thalamus, hypothalamus, and anterior and
posterior cerebral cortex (also called the secondary visual cortex).
Since human patients also exhibit substantial spongiosis in their
brain,thismodeliswelladaptedforevaluatingtherapeuticstrategies.
As previous injections performed in healthy mice showed the
potential use of lentiviral vectors in gene therapy [28], our objectives
was to administer dominant negative virions to evaluate their
efficiency in the curative treatment of prion diseases (Figure 1B). We
had previously shown that in situ injections are more efficient to
transduce the parenchyma cells than the intracerebroventricular
injections [28], so we decided to perform in situ injections into the
hippocampalregion.Indeed,thisstructureisthemostaffectedbythe
spongiosis which can be detected as early as 84 days inthe C57Bl/6J
miceinfected withthe Me7 prion strain(Figure1B)[34].In addition,
the hippocampal structure is involved in memory processes severely
deteriorated in prion diseases.
Production of lentivirus was carried out and PrP expression was
validated in Prnp
2/2 cells. The dominant negative inhibition was
confirmed in prion-infected cells, as described in Crozet et al. [28].
The possible curative effect of the treatment was assayed at two
different stages: at 35 days p.i., which is the beginning of the
neuroinvasion,andat105daysp.i.,oncethebraintissuesarealready
dammagedcorrespondingtoa verylatetreatment [34].At35or105
days p.i. with prions, mice received 2610
5 T.U. of lentivirus
containing either the GFP gene or the PrPQ167R gene. Mice
treated with YPrPQ167R at 35 days p.i.exhibited a delay of19 days
(12%), which is a statistically significant difference from the PBS or
YGFP treated groups, according to statistical analysis (p,0.001)
(Table 1). Interestingly, the group of mice treated at 105 days p.i.
seemed to have a delay of 9.3 days (6%). Only a single injection was
necessary to obtain these results that encouraged us to pursue the
dominant negative treatment strategy to enhance protection.
Then, we implemented a system of guide cannula implantation
to allow chronic injections directly into the brain (Figure 1C).
According to the previous assays with unique injection, we choose
to administer the treatment in mice at 80 and 95 days p.i both
because: (i) it corresponds to the beginning of the spongiosis in
mice brain [34]; (ii) the expression of PrPQ167R proteins after
virions integration in cells is stable during two months, allowing
the presence of dominant negative proteins in the mice brain up to
the terminal stage of the disease; (iii) a limited number of injections
can be done through the cannula because after 1 month the
aperture is blocked by tissue.
Seventy days post-infection (p.i.) with prions, 22 mice
underwent surgery to implant a guide cannula into the brain
using a stereotaxic frame. Two mice died: one during the surgery,
and the other the following day due to brain haemorrhage. The
guide cannula can remain implanted in the skull for several
months without any problems (Figure 1C).
At 80 and 95 days p.i. with prions, mice received 2610
5 T.U. of
either YGFP or YPrPQ167R (Table 1). We tried to perform a
third injection but we encountered many troubles linked to the
cannula completely clogged 30 days after it has been fixed on the
brain. Prion-inoculated mice treated with YPrPQ167R showed a
mean incubation time of 187.562.0 days. This result corresponds
Table 1. Survival time after administration of treatment to mice.
Mouse Nbr.
Prions
Inoculum
Cannula
Fixation
A Treatment
Mean Survival
Time days6s.e.m.
Delay vs PBS-treated
mice
B days (%) p value
G
13 Me7 No PBS 157.460.9 - -
5 Me7 No YGFP
C 158.260.9 - -
5 Me7 No YPrPQ167R
C 176.660.2 19.2 (12%) p,0.001
4 Me7 No YPrPQ167R
D 166.760.6 9.3 (6%) p=0.1
7 Me7 Yes YGFP
E 164.363.8 6.9 (4%) p=0.08
7
F Me7 Yes YPrPQ167R
E 187.562.0 30.1 (20%) p,0.001
AGuide cannulae were fixed in the hippocampal brain region of mice at 70 days p.i. with prions.
BDelay was calculated in comparison with the Me7 inoculated mice that received PBS.
COne unique injection of lentiviral treatment, either YPrPQ167R or empty virus YGFP, was administered in mice at 35 days p.i. with prions.
DOne unique injection of YPrPQ167R was administered in mice at 105 days p.i. with prions.
ETwo injections of lentiviral treatment, either YPrPQ167R or empty virus YGFP, were administered in mice at 80 and 95 days p.i. with prions through the cannula.
FOne mouse did not received properly administration of the lentiviral treatment YPrPQ167R since its cannula was blocked, not taken for statistical analysis.
Gp value was calculated using Scheffe ´ test, by comparison of each group of mice versus PBS-treated animals.
doi:10.1371/journal.pone.0002773.t001
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which is a statistically significant difference from the PBS treated
groups according to statistical analysis (p,0.001) (Table 1). Two
mice treated with YPrPQ167R even survived the scrapie infection
for as long as 193 days. This result was quite remarkable
compared to previously reported treatment targeting the late stage
of the diseases where massive dose and repeated injections or
continuous administration via pump, were necessary to prolong
the survival time of animals [10]. No significant differences in the
mean incubation time were observed between prion-infected
control mice treated with PBS (157.460.9 days) (Table 1) or mice
implanted with a guide cannula without treatment (159.064.1
days, n=2). This result suggests that the fixation of the guide
cannula in the mouse brain did not accelerate the appearance of
the clinical symptoms. Mice treated with YGFP showed a mean
incubation time of 164.363.8 days (4% survival time), which was
not significantly different from prion-infected control mice injected
with PBS according to Scheffe ´ test (p=0.08) (Table 1). Healthy
control mice received 2610
5 T.U. of YPrPQ167R at 80 and 95
days to test for possible toxicity of the treatment (n=3). They did
not exhibit a lethal toxic effect after treatment and were sacrificed
while still healthy at 273 days after the date of prions inoculation in
the other groups. Kaplan-Meier survival plots for each group
illustrated the prolongation of the incubation period in all the
treated animals (Figure 2 A–C).
Improvement of behaviour in cannula-implanted mice
treated with YPrPQ167R
Movies were successively made at 160, 172 and 189 days p.i. to
compare the global behaviour of mice infected with the Me7 prion
Figure 2. Kaplan-Meier survival plots of C57Bl/6J mice treated with lentiviral vectors. Mice inoculated with ME7 prion strain were
administered with either : (A) one unique injection of PBS or YGFP or YPrPQ167R at 35 days p.i.; (B) one unique injection of PBS or YGFP or
YPrPQ167R at 105 days p.i.; (C) two injections of PBS or YGFP or YPrPQ167R at 80 and 95 days p.i., through a cannula implanted in the mice brain.
Healthy mice were treated with YPrPQ167R at 80 and 95 days p.i.
doi:10.1371/journal.pone.0002773.g002
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well as healthy mouse treated with YPrPQ167R (see supplemen-
tary Movies S1, S2, S3 and S4). At the terminal stage of the
disease, the behaviour of PBS-treated mice (movie taken at 160
days p.i.) and YGFP-treated mice (movie taken at 172 days which
is the incubation period of the last YGFP-treated mouse)
alternated between hyperactivity and lethargic periods during
which animals were prostrated. They also exhibited kyphosis,
ruffled coat, and incontinence. Mice become unbalanced and
displayed combined cognitive impairments such as vision troubles
and environmental perception deficits. At 160 days, mice treated
with YPrPQ167R did not present any clinical signs. Movie taken
at 172 days showed that mice treated with YPrPQ167R did not
present the clinical signs describe above, although we did notice
mild hyperactivity and visible mild ataxia when the animal was
placed on top of the cage, indicating that it was already affected by
the prion disease. Therefore, our results show that the dominant
negative virions improved the global behaviour of the mice during
the survival time.
PrP
Sc deposits analysis in the brains of cannula-implanted
mice treated with YPrPQ167R
Brain homogenates from healthy mice treated with
YPrPQ167R and sacrificed while they were still healthy were
subjected to limited proteolysis. As expected, they showed no
detectable PrP
Sc bands (Figure 3A). All the brain homogenates
from Me7-inoculated mice treated with either PBS, YGFP, or
YPrPQ167R exhibited equivalent amount of PrP
Sc at the terminal
stage of the disease. This result is in agreement with those obtained
by Genoud et al. (2008) [36], where they observed equivalent
amount of PrP
Sc deposits at the terminal stage of the disease for
YPrPFc-treated mice versus PBS-treated animals. Although, we
noticed that one brain from a mouse treated with YPrPQ167R
and sacrificed at 186 days showed globally lower levels of PrP
Sc
(Figure 3A). Immunohistological analysis of brains from the first
two dead mice (182 and 186 days p.i.) in the YPrPQ167R-treated
group revealed fewer PrP
Sc deposits than PBS-treated mice
(Figure 3B). A combination of the treatment effect with a shorter
survival time in YPrPQ167R-treated mice (182, 186 days versus
Figure 3. Analysis of PrP
Sc accumulation in the brains of mice after treatment with lentiviral vectors. Immunoblot analysis of brain
homogenates before and after proteinase K digestion (A). Control mice were either not inoculated with prions or were inoculated with Me7. Mice
inoculated with the Me7 prion strain and implanted with a guide cannula received injections of either PBS, lentivirus carrying the GFP gene, or
lentivirus carrying the PrPQ167R gene. The numbers below indicate the dates when the mice were killed in days post-inoculation with prions (d.p.i).
The numbers to the right of each blot indicate the molecular mass of the protein standards in kDa. A mix of anti-PrP antibodies was used to stain
blots of SDS-polyacrylamide gels. Immunohistochemical detection of PrP
Sc deposits in the thalamus sections (B). The plus (+) and minus (2) signs
indicate that the mice were or were not inoculated with the ME7 prion strain and whether they were injected with PBS or PrPQ167R virions. Tissue
labelling was performed on 9 animals (3 per group). Pictures are representative of the staining observed in different animals in each group. Arrows
indicate the localization of the PrP
Sc deposits in the tissue sections. Bar, 6 mm.
doi:10.1371/journal.pone.0002773.g003
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Sc accumulated at
the terminal stage of the disease (Figure 3A–B).
Brain spongiosis in the vicinity of the guide cannula
Tissue sections close to the injection site (coordinates : L:
1.2 mm; R: 21.8 mm; P: 22.0 mm) showed equivalent vacuol-
isation in the hippocampus and thalamus regions of prion-infected
mice treated either with PBS, YGFP, or YPrPQ167R (Figure 4A–
C). However, the mice injected with the dominant negative virions
survived 30 days longer than control animals and might have a
propensity to develop a higher number of vacuoles and/or larger
vacuoles in their brain. A striking difference in spongiosis was
observed in the secondary visual cortex (Figure 5, Scheme a–b), an
area used to establish vacuolization profiles in standard procedures
and located above the injection site (coordinates : L: 0.2 mm; R:
21.8 mm; P: 20.3 mm). A comparison of the secondary visual
cortex of both hemispheres showed that there were three times
more vacuoles in the non-cannula side of the brain 288624 than
in the cannula side 107616 (ANOVA, PLSD Fisher test, n=3,
p,0.005). In addition, the vacuoles in the non-cannula side were
larger: the total vacuolar area in the treated side was
1,1626333 mm
2 compared to 22,52167, 242 mm
2 in the other
side of the brain (ANOVA, PLSD Fisher test, n=3, p,0.05). The
absence of neurodegeneration in the secondary visual cortex
suggested that the YPrPQ167R had a protective effect on the
tissue surrounding the injection site.
Substantial decrease in spongiosis in the injected side of
the brain far from the cannula implantation
Tissue sections more distant from the cannula implantation site
(R: 24.8 mm, 3 mm distant from the injection site) showed
extensive spongiosis that spread into the cortical regions of the brain
(Figure 6), probably due to the prolonged survival of the animals. A
strong difference was observed between the two hemispheres. We
estimated the total vacuolar area on the treated side to be
6,9756436 mm
2 compared to 13,8406766 mm
2 on the other side
ofthebrain(ANOVA,PLSDFishertest,n=4,p,0.0005)(Figure6).
The enlargement of the vacuoles could be due to the fusion of
smaller vacuoles since the animals survived longer.
Strong decrease in astrocytic gliosis in the brain of mice
receiving dominant negative lentiviral vectors
Immunohistochemistry for GFAP, a marker for inflammation
through astrocytic gliosis, was performed in different structures of
the mouse brain. Thalamus, as well as hippocampal (data not
shown), sections of healthy mice treated with YPrPQ167R showed
very minor GFAP labelling, illustrating the absence of inflamma-
tory processes that could have been activated by the lentiviral
particles (Figure 7A). Me7-inoculated mice receiving either PBS or
YGFP injections showed high levels of GFAP labelling in
thalamus, testifying to the presence of astrocytic gliosis consecutive
to the prion disease alone (Figure 7B–C). Surprisingly, Me7-
inoculated mice treated with YPrPQ167R exhibited a very low
Figure 4. Histological analysis of brain tissue sections. All the tissue sections were stained with hematoxylin and eosin and examined
histologically to confirm prion pathology as evidenced by the presence of vacuoles. The plus (+) signs indicate that the mice were inoculated with the
ME7 prion strain. Mice received two injections of either PBS (row A), lentivirus carrying the GFP gene (row B), or lentivirus carrying the PrPQ167R gene
(row C). Frontal tissue sections selected in the panel correspond to the numbers indicated in the schema on the top left. Coloured areas in the
schema correspond to anatomical sites referenced for the establishment of vacuolization profiles. Pathological analysis was performed on three
independent brains from each category of mice. Bar, 21 mm.
doi:10.1371/journal.pone.0002773.g004
Gene Therapy of Prion Diseases
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2773rate of GFAP staining (Figure 7D). Estimating the number of
GFAP-positive cells with the Mercator software confirmed the
histological results. For instance, only 1.860.5 GFAP positive cells/
10,000 mm
2 were counted in healthy mice treated with
YPrPQ167R, while 127611 and 136610 GFAP-positive cells/
10,000 mm
2 were counted in prion-infected mice injected with PBS
or YGFP, respectively (ANOVA, PLSD Fisher test, n=5,
p,0.0001) (Cf. Legend and Figure 7). Surprisingly, prion-infected
mice injected with YPrPQ167R had 2162 GFAP-positive cells/
10,000 mm
2, a significant difference from the PBS- and YGFP-
Figure 5. Less spongiosis in the vicinity of the guide cannula in prion-infected mice treated with YPrPQ167R. Tissue sections were
stained with hematoxylin and eosin. Letters a and b on the schema correspond to the secondary visual cortex (SVC) and a part of the hippocampal
CA1 region. Bars, 6 mm. Histograms represent either the mean number of vacuoles or the mean total vacuolar surface in the SVC areas. The number of
vacuoles was counted in one square of 250,000 mm
2, corresponding to nearly all the SVC surface, and repeated in three independent sections. The
total vacuolar area was determined by drawing the contour of each vacuole present in one square of 2,500 mm
2 using Mercator software (Explora
Nova, La Rochelle, France), which was repeated in three independent sections from the same mouse. The histograms represent the means6s.e.m.
Statistical analysis was performed using STATVIEW 5 software. Values were analyzed by ANOVA followed by the PLSD Fisher test (n=3). The number
of vacuoles in the treated side was statistically different from the non-treated area (**, p,0.005). The total vacuolar area in the cannula side was
statistically different from that in the non-cannula side (*, p,0.05).
doi:10.1371/journal.pone.0002773.g005
Figure 6. Neurodegeneration in brain regions distant from the guide cannula in prion-infected mice treated with YPrPQ167R. Tissue
sections were stained with hematoxylin and eosin. (1) and (3) correspond to the ipsilateral and contralateral sides of the brain, respectively, in a
coronal section located at 3 mm from the cannula implantation site. (2) corresponds to the thalamus area. Bars, 21 mm. The histogram represents the
mean total surface of vacuoles in areas 1 and 3. The total vacuolar area was determined in one mouse by drawing the contour of each vacuole
present in four squares of 40,000 mm
2 each, using Mercator software. The histogram represents the means6s.e.m. Statistical analysis was performed
using STATVIEW 5 software. Values were analyzed by ANOVA followed by the PLSD Fisher test (n=4). The total vacuolar area in the treated side was
statistically different from that in the non-treated area (***, p,0.0005).
doi:10.1371/journal.pone.0002773.g006
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from thehealthymice(ANOVA,PLSDFishertest,n=5,p=0.083).
This result shows that prion-infected mice administered dominant
negative virions have decreased astrogliosis in their brains.
Comparative analysis of the GFAP staining in the hippocampus
and thalamus was performed in Me7-inoculated mice receiving
either YGFP or YPrPQ167R (Figure 8A–F). The intensity of GFAP
labelling in tissue sections from mice treated with YGFP increased
with increasing distance from the injection site (hippocampus
cannula side: 7069 GFAP cells/10,000 mm
2; hippocampus non-
cannula side: 143614 GFAP cells/10,000 mm
2; ANOVA, PLSD
Fisher test, n=5, p,0.0001)(Figure 8A vs 8C; Figure 8G). By
contrast, tissue sections from mice treated with YPrPQ167R
exhibited mild GFAP staining regardless of the location of the
injection site (hippocampus cannula side: 1562G F A Pc e l l s /
10,000 mm
2; hippocampus non-cannula side: 2164G F A Pc e l l s /
10,000 mm
2, ANOVA, PLSD Fisher test, n=5, p=0.6) (Figure 8D
vs 8F; Figure 8G). This result is extremely interesting as it suggests
either that the lentiviral particles diffused throughout the brain or
that the mutant proteins expressed following virion integration, were
propagated from cell to cell, possibly through exosomes [37].
Discussion
Here, we described an innovative gene therapy approach that
takes advantage of the natural dominant negative properties of the
sheep PrPQ171R and human PrPE219K polymorphisms, both of
which are known to be capable of preventing prion diseases. Our
aim was also to develop a curative treatment protocol that would be
adaptable to human therapeutics, as treatment of CJD patients
necessarily starts late. In view of this, we have targeted two critical
events during the disease progression: at 35 days p.i. which is the
beginning of the neuroinvasion, and at 105 days p.i., when the brain
isalreadydeterioratedwith presenceof spongiosis[34]. Remarkably,
YPrPQ167R-treated mice at 35 days p.i. survived 19 days (12%)
longer than the control group. This result is in good agreement with
those of Genoud et al. (2008) [36] who recently reported the use of
lentiviral vectors for delivering the soluble prion antagonist PrP-Fc2:
in their strategy, RML-infected C57Bl/6 mice treated with YPrP-
Fc2 at 30 days p.i., increased their survival time by 25 days (15%).
Although the synthetic prion antagonist PrP-Fc2 is very different
from the natural dominant negative mutant PrPQ167R, those two
genetherapystrategies gaveverysimilar results.Thesmalldifference
in the incubation time is probably due to: (i)a ni n f e c t i o u sd o s eo f
prions which is lower than the one we used (3610
2 LD50 with an
incubation time of 17768 days for PBS-treated mice); (ii)ad o s eo f
lentivirus much higher (1.5610
9 infectious unit compared to
2610
5 T.U.), and (iii) the treatment that was started earlier during
the development of the disease in their model. Genoud et al. (2008)
have also observed that a huge administration of YPrP-Fc2 at 121
days p.i (1.5610
9 infectious unit in 30 ml) in mice brain modified the
kinetic of disease progression. [36].
Strikingly, YPrPQ167R-treated mice at 105 days p.i. survived
9.3 days (6%) more than the control group. Only a single injection
was necessary to increase the lifespan of animals and highlights the
very potent antagonist effect of the dominant negative
YPrPQ167R. Such interesting results, along with previous studies
showing that the anti-prion effect of dominant negative mutants is
Figure 7. Immunohistochemistry for GFAP in thalamus sections close to the injection site. The plus (+) and minus (2) signs indicate that
the mice were or were not inoculated (A), respectively, with the ME7 prion strain. Mice received two injections of either PBS (B) or lentivirus carrying
the GFP (C) or PrPQ167R genes (D). GFAP labelling was performed on nine independent brains (3 per group). The sections presented here are
representative of the global labelling in the thalamus. Bars, 6 mm. Histograms represent the mean number of GFAP-labelled cells in one mouse of
each treated group, which was measured by counting the GFAP-positive cells in five squares of 10,000 mm
2 each, using Mercator software. The
histograms represent the means6s.e.m. Statistical analysis was performed using STATVIEW 5 software. Values were analyzed by ANOVA followed by
the PLSD Fisher test (n=5). Multiple comparison analysis between A, B, C, and D showed that they were all statistically significant (***, p,0.0001),
except for A versus D and B versus C.
doi:10.1371/journal.pone.0002773.g007
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this strategy to enhance protection via chronic injections. Thus, we
implemented a system of guide cannula implantation directly into
the brain as an alternative to the osmotic pump since lentiviral
particles are not stable at room temperature. After just two
injections of dominant negative YPrPQ167R into prion-infected
mice at 80 and 95 days p.i., we observed a prolongation of the
incubation time of 30 days, accompanied by a striking improve-
ment in the behaviour of the animals. Importantly, this delay was
correlated with: (i) a reduction in the spongiosis in the cannula side
of the brain which is all the more evident that we are far from the
injection site; and (ii) a remarkable decrease in astrocytic gliosis
throughout the brain. Our results strongly suggest that the
YPrPQ167R reduced inflammation process in the brain.
Together, these results demonstrate that the combination of
dominant negative lentiviral vectors and chronic injection into the
brain through a guide cannula is a promising approach for the
curative treatment of prion diseases.
How does the dominant negative PrPQ167R variant increase
the incubation time of the disease? In vivo and in vitro studies have
shown that PrPQ167R cannot itself be converted into its infectious
PrP
Sc isoform and can also prevent the conversion of wt PrP
C into
wt PrP
Sc via a competitive interaction between PrPQ167R and
PrP
C for PrP
Sc [21,22,27]. Dominant negative inhibition in
transgenic mice prolongs survival time by slowing the rate of
PrP
Sc accumulation in infected animals [27]. We have shown here
that mice treated with YPrPQ167R display a prolonged survival
time although the PrP
Sc levels in terminally sick mice are not
significantly reduced. By contrast to transgenic mice, the presence
of substoichiometric PrPQ167R delivered by lentivirus may not be
sufficient to completely block PrP
Sc formation.
Besides, the substantial decrease of GFAP labelling in the brain
suggests that PrPQ167R might play a key role in interfering with
the mechanism that activates the inflammatory process. A recent
study on prion-infected cells showed that only the PrP
Sc isoform
interacts with neurons and thereby triggers the recruitment of
microglia, leading to upregulated expression of the chemokine
RANTES [38]. Activated microglia release various factors, such as
cytokines and free radicals, that induce neuronal apoptosis but
maintain glial survival [39]. It is possible that YPrPQ167R slows
down the accumulation of PrP
Sc during the disease progression,
and as a consequence may diminish the microglia recruitment that
activates the inflammatory process.
The prospects for successful gene therapy for prion diseases are
often downplayed on the basis that the number of targeted CNS
regions is limited, and also because tissue transduction is relatively
inefficient and can be constrained by the infectious titer of the
virions or the need to target specific cell types. Importantly, our
results address these criticisms, as we observed a widespread
reduction in astrocytic gliosis, suggesting that the lentiviral
particles and/or the dominant negative proteins were able to
diffuse far from the injection site which was also observed by
Genoud et al. (2008) in their study [36]. Protein propagation
would likely occur through cell to cell contacts involving small
cellular vesicles of endosomal origin called exosomes, which have
been proposed to contribute to the spread of prions [37]. A
mechanism proposed by Genoud et al., to explain the neuropro-
tective effect far from the injection site is the propagation of anti-
prion antagonist proteins via a noncell autonomous manner [36].
Importantly, this gene therapy approach is effective even when
started at a late stage of prion infection. Our results thus represent
a promising advance towards a possible curative treatment for
prion diseases in humans.
Supporting Information
Movie S1 Healthy C57Bl/6 mouse with a guide cannula
implanted into its brain and treated with PrPQ167R virions.
Movie was recorded at 172 days post-infection with prions, on a
mouse representative from the group.
Found at: doi:10.1371/journal.pone.0002773.s001 (0.91 MB MOV)
Movie S2 Prion-inoculated C57Bl/6 mouse with a guide
cannula implanted into its brain and treated with GFP virions.
This animal is representative from a group of mice that was
treated with GFP virions at 80 and 95 days post-infection (p.i.)
with prions. The movie was recorded at 172 days p.i.
corresponding to the terminal stage of the disease.
Found at: doi:10.1371/journal.pone.0002773.s002 (0.91 MB MOV)
Figure 8. GFAP labelling in tissue sections of prion-infected mice treated with YGFP or YPrPQ167R. The plus (+) signs indicate that the
mice were inoculated with the Me7 prion strain. Mice received two injections of either YGFP (A, B and C) or YPrPQ167R (D, E and F). The section
presented here are representative of the global labelling in the cortex, both in the cannula side (A and D) or non-cannula side (C and F) and in the
thalamus (B and E). Bars, 6 mM. The histogram represents the mean number of GFAP-labelled cells in one mouse per group, which was measured by
counting GFAP-positive cells in five squares of 10,000 mm
2 each using Mercator software. The histogram represents the means6s.e.m. Statistical
analysis was done using STATVIEW 5 software. Values were analyzed by ANOVA followed by the PLSD Fisher test (n=5). Multiple comparison analysis
among A, B, C, D, E, and F showed that they were all statistically significant (***, p,0.0001), except for B versus C, and D versus E versus F.
doi:10.1371/journal.pone.0002773.g008
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cannula implanted into its brain and treated with dominant
negative PrPQ167R virions. This animal is representative from a
group of mice that was treated with PrPQ167R virions at 80 and
95 days post-infection (p.i.) with prions. The movie was recorded
at 172 days p.i. that is the moment when control groups have been
killed.
Found at: doi:10.1371/journal.pone.0002773.s003 (1.21 MB MOV)
Movie S4 Prion-inoculated C57Bl/6 mouse with a guide
cannula implanted into its brain and treated with dominant
negative PrPQ167R virions. This animal is representative from a
group of mice that was treated with PrPQ167R virions at 80 and
95 days post-infection (p.i.) with prions, and presenting survival
times lasting from 182 days p.i. to 193 days p.i. The movie was
recorded at 189 days p.i. at the terminal stage of the disease.
Found at: doi:10.1371/journal.pone.0002773.s004 (0.61 MB MOV)
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